Substance / Medication

Tizanidine

Overview

Active Ingredient
tizanidine
RxNorm CUI
57258

Indications

DOSAGE AND ADMINISTRATION Tizanidine tablet is a short-acting drug for the management of spasticity. Because of the short duration of effect, treatment with tizanidine should be reserved for those daily activities and times when relief of spasticity is most important (see).

Labeler: New Horizon Rx Group, LLCUpdated: 2013-12-27T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

1/2 max WARNINGS CLINICAL PHARMACOLOGY: Drug Interactions Concomitant use of tizanidine with fluvoxamine or with ciprofloxacin, potent inhibitors of CYP1A2, is contraindicated. Significant alterations of pharmacokinetic parameters of tizanidine including increased AUC, t, C, increased oral bioavaila

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Baclofen and Tizanidine Adverse Effects Observed Among Community-Dwelling Adults Above the Age of 50 Years: A Systematic Review.
Killam-Worrall Lisa, Brand Romana, Castro Janine R et al. · Ann Pharmacother · 2024
PMID: 37589096Meta-Analysis
Tizanidine for the management of acute postoperative pain after inguinal hernia repair: A placebo-controlled double-blind trial.
Yazicioğlu Dilek, Caparlar Ceyda, Akkaya Taylan et al. · Eur J Anaesthesiol · 2016
PMID: 26555871RCT
Amitriptyline versus tizanidine in the management of tension-type headache in Nepal.
Thapa Ajay Singh · Emerg Med Australas · 2013
PMID: 24224929RCT
Eperisone versus tizanidine for treatment of chronic low back pain.
Rossi M, Ianigro G, Liberatoscioli G et al. · Minerva Med · 2012
PMID: 22653094RCT
Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine.
Backman Janne T, Schröder Marika T, Neuvonen Pertti J · Eur J Clin Pharmacol · 2008
PMID: 17955229RCT
Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.
Backman Janne T, Granfors Marika T, Neuvonen Pertti J · Eur J Clin Pharmacol · 2006
PMID: 16758262RCT
Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects.
Backman Janne T, Karjalainen Marjo J, Neuvonen Mikko et al. · Br J Clin Pharmacol · 2006
PMID: 16934051RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tizanidine (substance)
SNOMED CT
373440006
UMLS CUI
C0146011
RxNorm CUI
57258
Labeler
New Horizon Rx Group, LLC

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.